Immunic's CALLIPER Phase 2 Misses Primary Endpoint; Progressive MS Phase 3 Planned for H1/2027
IMUX sits 62% above its 52-week low of $5.062.
Summary
Immunic disclosed CALLIPER Phase 2 progressive MS data showing the primary brain-volume endpoint was not met (4.7% relative difference, P=0.78), while exploratory disability measures trended favorably. The company will advance a ~1,400-patient Phase 3 (PROTECT-MS) with first-patient-enrolled expected in H1/2027.
Key Events · Product Development and Regulatory · IMUX
-
CALLIPER Phase 2 Primary Endpoint Missed
Annualized percent brain volume change at 30 months showed a 4.7% relative difference versus placebo (95% CI -0.285 to 0.379; P=0.78), so statistical significance was not achieved.
-
Exploratory Disability Signals Favor Drug
24-week confirmed disability improvement hazard ratio was 2.44 (1.07-5.58), nominally significant, and the win ratio showed patients 1.5x more likely to have a beneficial disability outcome (nominal p=0.042).
-
Regional Atrophy Trends, Not Significant
At 30 months, regional atrophy differences favored vidofludimus calcium at 15.7% for gray matter, 10.0% for cortical gray matter and 35.0% for thalamus, though statistical significance was not achieved.
-
PROTECT-MS Phase 3 Design Disclosed
The Phase 3 trial targets roughly 1,400 patients with non-active SPMS or PPMS, uses confirmed disability worsening or the 9-hole peg test as the primary endpoint, and expects first-patient-enrolled in H1/2027.
Analysis · IMUX · Life Sciences
The progressive MS program is now quantified, and the headline is a miss: CALLIPER's primary endpoint — annualized percent brain volume change at 30 months — showed only a 4.7% relative difference versus placebo (P=0.78). What keeps the story alive is the exploratory layer: a nominally significant 24-week confirmed disability improvement hazard ratio of 2.44 and a 1.5x win ratio (nominal p=0.042), plus favorable trends in gray matter, cortical gray matter and thalamus atrophy that did not reach significance. Immunic is proceeding with PROTECT-MS, a ~1,400-patient Phase 3 in non-active SPMS and PPMS with first-patient-enrolled expected in H1/2027, so the progressive MS bet now rests on a disability endpoint rather than the imaging endpoint that failed. The near-term stock driver remains the relapsing MS ENSURE-1/ENSURE-2 top-line data expected in December 2026, with a targeted NDA submission in mid-2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMUX was trading at $8.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.3M. The 52-week trading range was $5.06 to $17.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.